%0 Journal Article
%T mTOR inhibitor in the treatment of Hodgkin¡¯s lymphoma: a case report
%A Ibeas P
%A Cantos B
%A Provencio M.
%J Blood and Lymphatic Cancer: Targets and Therapy
%D 2011
%I 
%R http://dx.doi.org/10.2147/BLCTT.S24910
%X hibitor in the treatment of Hodgkin¡¯s lymphoma: a case report Case report (1483) Total Article Views Authors: Ibeas P, Cantos B, Provencio M. Published Date November 2011 Volume 2011:1 Pages 19 - 22 DOI: http://dx.doi.org/10.2147/BLCTT.S24910 Patricia Ibeas, Blanca Cantos, Mariano Provencio Clinical Oncology Department, Hospital Puerta de Hierro Majadahonda, Madrid, Spain Abstract: Hodgkin¡¯s disease is curable in 90% of the cases diagnosed in early stages (I and II) and in 70% of all patients who suffer from the disease. Refractory disease occurs in 10%¨C15% of cases and is still a clinical challenge. Its treatment is based on intensive chemotherapy regimens with transplantation, but there are patients who relapse after transplantation who have a poor prognosis. At this point in time, there is a lack of effective treatment options with proven efficacy and there is a real need to investigate new treatment drugs with different mechanisms of action. A persistent activation of mTOR signaling has been identified in leukemia, Hodgkin¡¯s and non-Hodgkin¡¯s lymphoma, and multiple myeloma. Everolimus, an mTOR kinase inhibitor, is being used as an option in these cases with encouraging results. Here, the authors report their experience with a patient treated with everolimus.
%K everolimus
%K positron emission tomography
%K chemotherapy
%U https://www.dovepress.com/mtor-inhibitor-in-the-treatment-of-hodgkinrsquos-lymphoma-a-case-repor-peer-reviewed-article-BLCTT